#1
The elevating prevalence of chronic diseases, such as cancer, is primarily driving the growth of the global tanespimycin market. Moreover, the expanding geriatric population, who are more prone to these illnesses, is further creating a positive outlook for the market. In addition to this, the growing use of tanespimycin for the treatment of kidney tumors, pediatric acute lymphoblastic leukemia, lung cancer, HER-2-positive breast cancer, etc., is also propelling the market growth.
loading